Centiva Capital’s Bristol-Myers Squibb BMY Stock Holding History

Centiva Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.9M	Sell	1,004,600 -115,600	-10%	-$6.64M	0.51%	40
2026 Q1	$67.9M	Buy	1,120,200 +246,200	+28%	+$14.4M	0.5%	39
2025 Q4	$47.1M	Buy	+874,000	New	+$42M	0.38%	52
2024 Q2	–	Sell	-20,700	Closed	-$1.12M	–	2081
2024 Q1	$1.12M	Buy	+20,700	New	+$1.05M	0.03%	615
2023 Q4	–	Sell	-10,000	Closed	-$580K	–	1824
2023 Q3	$580K	Buy	+10,000	New	+$613K	0.01%	887
2023 Q2	–	Sell	-24,500	Closed	-$1.7M	–	1648
2023 Q1	$1.7M	Sell	24,500 -43,000	-64%	-$3.03M	0.04%	452
2022 Q4	$4.86M	Sell	67,500 -20,100	-23%	-$1.52M	0.14%	161
2022 Q3	$6.23M	Sell	87,600 -22,000	-20%	-$1.6M	0.12%	119
2022 Q2	$8.44M	Buy	109,600 +42,100	+62%	+$3.21M	0.2%	70
2022 Q1	$4.93M	Buy	67,500 +47,700	+241%	+$3.2M	0.09%	178
2021 Q4	$1.24M	Buy	19,800 +17,820	+900%	+$1.05M	0.03%	530
2021 Q3	$117K	Sell	1,980 -37,820	-95%	-$2.49M	0.01%	1017
2021 Q2	$2.66M	Buy	+39,800	New	+$2.6M	0.06%	263
2020 Q1	–	Sell	-35,900	Closed	-$2.3M	–	638
2019 Q4	$2.3M	Buy	35,900 +12,600	+54%	+$722K	0.11%	177
2019 Q3	$1.18M	Hold	23,300	–	–	0.07%	205
2019 Q2	$1.06M	Sell	23,300 -26,200	-53%	-$1.22M	0.06%	207
2019 Q1	$2.36M	Sell	49,500 -44,300	-47%	-$2.21M	0.16%	103
2018 Q4	$4.88M	Buy	93,800 +46,600	+99%	+$2.5M	0.39%	42
2018 Q3	$2.93M	Buy	+47,200	New	+$2.8M	0.25%	61

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centiva Capital's BMY Position: Q2 2026 in Review

Centiva Capital reduced its Bristol-Myers Squibb (BMY) stake by 41% in Q2 2026, selling an estimated $1.91M and leaving 48,515 shares worth $2.8M. The position accounts for 0.02% of the portfolio, ranked #372.

Centiva Capital first reported a position in BMY in Q3 2018 and has held it in 26 quarters since. The position peaked at $6.59M in Q4 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Centiva Capital held 48,515 shares of Bristol-Myers Squibb worth $2.8M as of Q2 2026.
Centiva Capital sold 33,218 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.91M.
Bristol-Myers Squibb made up 0.02% of Centiva Capital's portfolio in Q2 2026, its #372 holding.
Centiva Capital first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 26 quarters since.
Centiva Capital's Bristol-Myers Squibb position peaked at $6.59M in Q4 2025.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.